- [PRESSWIRE] CHALK RIVER, ON – June 25, 2025 — Fusion Fuel Cycles Inc. (FFC), a joint venture between Canadian Nuclear Laboratories and Kyoto Fusioneering, is pleased to announce that it has recently published two foundational papers for the company: “The Fusion Fuel Cycle Simulator — towards integrated dynamic process simulation of fusion fuel cycles” and “Conceptual Design of UNITY-2, the Fuel Cycle Test Facility for Fusion Pilot Plants.”
- [PRESSWIRE] TX, US – 09 June, 2025 — As Long as Parliamentarians Continue Funding CERN’s 20-Trillion-Transistor, 650 kW FPGA Systems (66 Operations), CERN Will Avoid a Public Comparison with Crosetto’s 6 kW 3D-Flow System (8,000+ Operations)
- A unique solution designed for students and teachers alike
- Valerann, a global leader in AI-powered, data-driven road traffic management solutions, has been awarded a €3.6M co-funded contract from the European Space Agency’s Business Applications and Space Solutions (BASS) program.
- [PRESSWIRE] FL, US – 31.12.24 — Discoveries made in 2024 regarding fertilizer reduction, increased production, carbon sequestration and initial proof of an anti-pathogen and microbiome culmination of 20 years of discoveries will pave the way for improved food equity and food security…
- [PRESSWIRE] China – 20 December, 2024 — A groundbreaking study published in Science has achieved a significant advancement in thermal photonics, enabling efficient subambient daytime radiative cooling for vertical surfaces.
- Pemberton has won grant funding for a 800,000 Euros project from European Space Agency and UK Space Agency to demonstrate biodiversity monitoring in grasslands and explore the implementation of monitoring systems for natural capital assets, with partners Ordnance Survey, Sainsbury’s and West Berkshire Council.
- [PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).
- André Moravec’s work builds an imaginary world to explain the physical world.
- André Moravec’s work builds an imaginary world to explain the physical world.
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] London, UK – 30.09.22 — COPTRZ Ltd, have launched their new drone learning experience platform (LXP) platform COPTRZ ACADEMY. COPTRZ claim that this is the leading platform of its type anywhere in the World.
- [PRESSWIRE] London, UK – 30.09.22 — COPTRZ Ltd, have launched their new drone learning experience platform (LXP) platform COPTRZ ACADEMY. COPTRZ claim that this is the leading platform of its type anywhere in the World.
- [PRESSWIRE] Austria – 04.07.22 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).
- [PRESSWIRE] LUBBOCK, TX — April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.
- [PRESSWIRE] London, UK – 14.04.22 — Zero Carbon Capital Ltd has today announced the first close of the new Zero Carbon Capital 2022 LP fund. They have raised £10m toward a target of £30m to invest in extraordinary early-stage European companies building innovative, scientific solutions to the biggest, hardest challenges of decarbonisation.
- [PRESSWIRE] Vienna – 23rd February 2022 — Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).
- [PRESSWIRE] Vienna – 03 February, 2022 — CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.
- • Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants • Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening • A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance
- [PRESSWIRE] Austria – 10.12.21 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).
- [PRESSWIRE] Vienna — 17th August 2021 – CEBINA GmbH, Central European Biotech Incubator and Accelerator today announces the publication of the first results of a Phase 2 efficacy clinical trial sponsored jointly with its partner URSAPHARM Arzneimittel GmbH demonstrating that a nasal spray containing the active ingredient azelastine was effective in accelerating the reduction of the viral load in SARS-CoV-2 positive patients. Azelastine has been marketed in an identical composition by URSAPHARM for many years and is used as an antiallergic.
- [PRESSWIRE] 03 August, 2021 — In the 1940s Albert Szent-Györgyi – a Nobel-prize winning Hungarian biochemist known for his work in science – wrote that “the future will be, like the schools are today”. In 2021, these words still ring true, even more so for the winners of the European Code League competition, Dr Corina Toma, Mihaela Giurgea and their students from Tiberiu Popoviciu High School of Computer Science in Romania. The second and third places went to teams from Turkey and Greece.
- Carbon Engineering and BeZero Carbon join forces to offer a new retail option for customers seeking to address their carbon footprint through Direct Air Capture technology. BeZero’s Carbon Rating Framework gives customers an additional tool to assess the quality of available solutions, with Direct Air Capture the only AAA+ top-rated solution.
- Frodeno is renowned as one of the greatest triathletes of his generation. The Olympic gold medalist will use the Supersapiens system to effectively manage his fueling strategy to continue in his pursuit of earning another Ironman World Championship title.
- [PRESSWIRE] Austria – 04 May, 2021 — CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.
- [PRESSWIRE] New York, NY – Art State Productions, Inc. announces the launch of a crowdfunding campaign for Journey of Life™, an educational animated series approaching education through entertainment for the healthy emotional development of the child.
- [PRESSWIRE] Vienna, Austria – 17 February, 2021 — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.
- [PRESSWIRE] Madrid, Spain – 25 January, 2021 — An innovative new technology from Necenti Labs offers 96% accuracy for COVID-19 detection before infection with deep data to give companies and individuals the power of knowledge to battle lockdown.
- [PRESSWIRE] SANTA ANA, January 26, 2021 — Airionex, the leading global provider of bi-polar ionization air and surface purification technology, announced today that it has hired Françoise Parker as Senior Vice President of Sales and Marketing. Françoise will report to CEO Jukka Matikka, and will be responsible for sales team leadership, accelerating Airionex revenue throughout North America, the development and management of key channels, and overseeing the company’s marketing strategy.
